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Background: Renal cell carcinoma (RCC) is one of the most common kidney cancers and is highly resistant to
chemotherapy. We previously demonstrated that 5-aza-20-deoxycytidine (DAC) could significantly increase the
susceptibility of renal cell carcinoma (RCC) cells to paclitaxel (PTX) treatment in vitro, and showed the synergy of
DAC and PTX against RCC. The purpose of this study is to investigated the gene transcriptional alteration and
investigate possible molecular mechanism and pathways implicated in the synergy of DAC and PTX against RCC.
Methods: cDNA microarray was performed and coupled with real-time PCR to identify critical genes in the
synergistic mechanism of both agents against RCC cells. Various patterns of gene expression were observed by
cluster analysis. IPA software was used to analyze possible biological pathways and to explore the inter-relationships
between interesting network genes.
Results: We found that lymphoid enhancer-binding factor 1 (LEF1), transforming growth factor β-induced (TGFBI),
C-X-C motif ligand 5 (CXCL5) and myelocytomatosis viral related oncogene (c-myc) may play a pivotal role in the
synergy of DAC and PTX. The PI3K/Akt pathway and other pathways associated with cyclins, DNA replication and
cell cycle/mitotic regulation were also associated with the synergy of DAC and PTX against RCC.
Conclusion: The activation of PI3K/Akt-LEF1/β-catenin pathway could be suppressed synergistically by two agents
and that PI3K/Akt-LEF1/β-catenin pathway is participated in the synergy of two agents.
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Renal cell carcinoma (RCC), a glandular carcinoma,
accounts for approximately 85% to 95% of adult malig-
nant kidney cancer cases [1]. Although surgical resection
can be curative for localized disease, prognosis of
advanced renal cell carcinoma is very poor with a five-
year survival rate of 5% to 10%. At present, no standard
treatment has been established for metastatic RCC, due
to its high resistance to conventional chemotherapy [2,3].
The response rates of immunochemical therapies com-
bined with chemotherapeutic agents with interferon-α or
interleukin-2 ranged from 2% to 39% [4,5].
The landscape for RCC treatment has changed dra-
matically in recent years, vascular endothelial growth* Correspondence: tianye6251@163.com
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reproduction in any medium, provided the orfactor (VEGF) receptor tyrosine phosphorylation inhibi-
tors (TKIs) and drugs that inhibit mammalian target of
rapamycin (mTOR) signaling have become the mainstay
for the management of metastatic RCC based on
improved progression-free survival or/and overall sur-
vival outcomes [6]. As new targeted strategies to control
renal cell carcinoma evolve, so do the strategies to meas-
ure response and predict outcome. Recently, more
efforts had focused on exploring the critical role of DNA
methylation in human carcinogenesis [7]. 5-Aza-20-
deoxycytidine (DAC), a nucleoside analogue, could in-
corporate into DNA and exert direct cytotoxic and
antiproliferative effects on tumor cells [8]. These
effects are mainly dependent on its interference with
DNA reparative machinery and inhibition of de novo
thymidine synthesis, as well as activation of proapop-
totic intracellular signaling [9]. The ability of DAC. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion and activation of cell cycle checkpoint signaling,
similarly to previous reports for DNA repair responses
[10,11]. These two activities may not be entirely inde-
pendent of each other given that the expression of
some genes involved in cell cycle regulation is epigen-
etically controlled.
Paclitaxel (PTX) is now considered a new type of
broad-spectrum and highly efficient anticancer drug,
and the efficacy of this agent on a variety of solid tumors
has been noted. PTX is an anticancer agent due to its ef-
ficient induction of apoptosis. It interferes with micro-
tubule assembly by binding and stabilizing b-tubulin in
the G2/M phase of the cell cycle [12]. We have previ-
ously examined the antiproliferative effects of DAC
alone, and of DAC with the various chemotherapeutic
agents, on RCC cells. Our results showed that DAC
combined with PTX synergistically inhibited the growth
of the RCC cell lines [13]. We also investigated the basic
mechanism of the synergy of DAC and PTX against
RCC cells; DAC inhibited cell growth by the induction
of G2/M cell cycle arrest, and the effect of PTX
depended on apoptosis induction and G2/M cell cycle
arrest. When treated with DAC and PTX together, a
higher percentage of cells in subG1 and G2/M phase
was observed compared to that in cells treated with
DAC or PTX alone. Although caspase inhibitors could
decrease PTX-induced apoptosis and the cytotoxicity of
PTX in RCC cells, they did not abolish the enhancement
of the susceptibility of RCC to PTX by DAC via G2/M
cell cycle arrest. However, the molecular mechanism and
pathways involved in the synergistic effect of these two
agents against RCC remain unclear.
In this study, we investigated the gene transcriptional
alteration by cDNA microarray and investigated possible
molecular mechanism and pathways implicated in the
synergy of DAC and PTX against RCC. Our results indi-
cated that several key regulatory genes and active path-
ways could be identified and they may play critical roles
in the synergy of DAC and PTX.
Methods
Cell culture and agents
Two RCC cell lines (human cells), ACHN and NC 65,
obtained from ATCC were cultured in RPMI-1640
medium (Gibco, Bio-Cult, Glasgow, Scotland, UK) sup-
plemented with 25 mM HEPES, 2 mM L-glutamine, 1%
nonessential amino acids, 100 units/ml penicillin,
100 μg/ml streptomycin, and 10% heat-inactivated fetal
bovine serum. Cell lines were maintained as monolayers
in 10 cm plastic dishes and incubated in a humidified at-
mosphere containing 5% CO2 at 37°C. Cells were treated
for three days. DAC and PTX were purchased from
Sigma-Aldrich, St Louis, MO, USA.RNA purification and cDNA preparation
ACHN and NC 65 cells were treated with DAC (1 μM),
PTX (1nM), DAC (1 μM)+PTX (1nM), or vehicle re-
spectively. Total RNAs are harvested using TRIzol (Invi-
trogen, Carlsbad, CA, USA) and the RNeasy kit (Qiagen,
Frankfurt, Germany) according to the manufacturer’s
instructions. 1 μg total RNA was used as starting mater-
ial for the cDNA preparation. After having performed
RNA measurement on the NanoDrop ND-1000 (Nano-
Drop Technologies, Wilmington, DE, USA) and de-
naturing gel electrophoresis, the samples were amplified
and labeled using the Agilent Quick Amp labeling kit
(Agilent Technologies, Santa Clara, CA, USA), utilizing
Cy5 and Cy3 fluorescent dye.
cDNA microarray
Hybridization with Agilent’s whole genome oligo micro-
array was performed in Agilent’s SureHyb hybridization
chambers. After hybridization and washing, the pro-
cessed slides were scanned with the Agilent DNA micro-
array scanner (part number G2505B) using settings
recommended by Agilent Technologies, and then quan-
titative analysis was conducted. The resulting text files
extracted from Agilent Feature Extraction software (ver-
sion 10.5.1.1) were imported into the Agilent Gene-
Spring GX software. Finally, genes that were upregulated
or downregulated more than 2.0-fold in comparison with
the control were selected and analyzed for further study.
Real-time PCR
Eighteen upregulated and downregulated genes were
chosen for verification by real-time PCR. PCR reaction
was carried out by Platinum SYBR Green qPCR Super-
Mix UDG kit (Applied Biosystems, Foster City, CA,
USA ). GAPDH gene was used as internal control. The
PCR thermal cycling was done by a Bio-Rad real-time
PCR machine (Bio-Rad Laboratories, Richmond, CA,
USA), and conditions performed for all of the samples
was as follows: samples were subjected to 40 amplifica-
tion cycles comprising denaturation at 95°C for 10 sec,
annealing at 60°C for 10 sec, and elongation at 72°C for
10 sec. Total RNA was isolated with RNeasy mini kit
(Qiagen) and the first-strand cDNA synthesis kit (Amer-
sham Biosciences, Little Chalfont, UK) was used for re-
verse transcription. Data collection was performed
during both annealing and extension, with two measure-
ments at each step and at all times during melt curve
analysis.
Western blot
We changed the treatment concentrations in this sec-
tion. Protein was extracted by lysis buffer, the protein
concentration was assessed by the Bradford dye-binding
protein assay (Bio-Rad), and then SDS polyacrylamide
Figure 1 Scanned images of cDNA microarray are displayed in
(A) and (B) and the result of hierarchical clustering on
conditions shows a distinguishable gene expression profiling
among samples. ‘Red’ indicates high relative expression, and ‘blue’
indicates low relative expression.
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Kinase p85 (19 H8)/phospho-PI3K p85 (Tyr458) Rabbit
mAb; Akt, (pan) (11E7)/phospho-Akt (Ser473) Rabbit
mAb were purchased from Cell Signaling Technology
(Danvers, MA, USA). An anti-β-actin monoclonal anti-
body (Abcam, Cambridge, UK) was used as an internal
control. The immune complexes were detected using a
system of enhanced chemiluminescence (ECL) combined
with Western blot (Amersham, Aylesbury, UK).
Ingenuity pathway analysis
Ingenuity pathway analysis (IPA) version 3.0 was used to
cluster genes for possible biological pathways and to ex-
plore the inter-relationships between interesting network
genes with particular patterns. To start building net-
works, the program queries the Ingenuity Pathway
Knowledge Base for interactions between Focus Genes
and all other gene objects stored in the knowledge base,
to generate a set of networks. IPA then computes a score
for each network according to the fit of the network to
the setoff focus genes. A detailed description of IPA can
be found on www.ingenuity.com. All up/down-regulated
genes (>2.0-fold) were picked up and analyzed by IPA to
reveal the key functions and pathways that participated
in the treatment of RCC by DAC and PTX.
Statistical analysis
All determinations were repeated in triplicate, and the
results were expressed as mean ± standard deviation
(SD). Statistical significance was determined by Student’s
t-test, and a P value of 0.05 or less was considered sig-
nificant. Calculations of synergy were made by isobolo-
graphic analysis, as described by Berenbaum [14].
Results
cDNA microarray and cluster analysis
Scanning images of cDNA microarray are displayed in
Figure 1A and 1B, Cy3 stands for the controls (green),
whereas Cy5 stands for treatment with DAC, PTX or
DAC+PTX (red). Hierarchical clustering was used to
produce gene or condition trees. The resulting trees
grouped genes (samples/conditions) together based on
the similarity of their expression profiles, which allow
the users to select groups with similar genes (samples/
conditions). The dendrogram shows the relationships
among the expression levels of conditions. Here, hier-
archical clustering was performed based on ‘all targets
value’. Our experiment consists of three different condi-
tions. The result of hierarchical clustering on conditions
shows a distinguishable gene expression profiling among
samples. The confirmation of the repeatability of the
synergy of DAC and PTX against RCC cells is shown in
Additional file 1.
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The top 10 up/down-regulated genes by the treatment
with DAC, PTX or DAC+PTX normalized against the
control were showed in Additional file 2: Table S1. The
expression of each gene in the different treated samples
was averaged and depicted as fold changes in compari-
son with the control. The threshold value used to screen
up- or down-regulated genes was set as absolute value
of log2 ratio ≥1.0 (fold change ≥2.0). Microarray data
were normalized by dividing spot intensities by the glo-
bal median. Normalized data were extracted, prepro-
cessed and sorted with Microsoft Excel.
Synergy-related genes of DAC and PTX
To identify the genes that were involved in the synergis-
tic effect of DAC and PTX against RCC growth, we
selected the genes that showed more than 2.0-fold
changes in the samples treated with DAC, PTX and
DAC+PTX than those in the control. The synergistic
score presents the relativity level of the gene in the syn-
ergy of both agents, and a higher value indicates this
gene may have participated in the effective interaction of
these two agents. The synergistic score was calculated
using the following formula: synergistic score = fold
changes regulated by DAC+PTX/(fold changes regu-
lated by DAC+ fold changes regulated by PTX). The
synergistic score of each gene was calculated by the aver-
age of ACHN and NC 65 and genes with the top 10 syn-
ergistic scores in this study are shown in Additional file
3: Table S2A and S2B.
Synergy-related pathways of DAC and PTX
The IPA software’s output is ranked in terms of prob-
ability and the least likely to have occurred by chance
will contain the largest number of disregulated genes
and presumably be of the greatest interest and indicative
of biologically relevant effects [15]. The canonical path-
ways involved in the synergy of DAC and PTX were
shown as the P value, and low P value represents the
pathway that is highly correlated with the synergy of
DAC and PTX against RCC. We selected the four
synergy-related pathways activated by DAC and/or PTX
simultaneously in ACHN and NC 65 cells. These path-
ways include Class I PI3K signaling events mediated by
Akt, amb2 integrin signaling, IL-2- and IL-23-mediated
signaling events (Additional file 3: Table S2C). All of the
four pathways could be activated by DAC and PTX
alone. Moreover, a lower P value was achieved by com-
bined treatment with DAC and PTX.
Confirmation of synergy-related genes
To confirm the repeatability of microarray data, nine
upregulated and nine downregulated synergy-related
genes were verified by real-time PCR. The primersequences used in this study are listed in Figure 2, and
results indicated that the expression of all 18 genes dis-
played similar synergistic score patterns to those identi-
fied in the original microarray data.
Suppression of PI3K/Akt pathway by DAC and/or PTX
To clarify how PI3K/Akt pathway is involved in the syn-
ergy of DAC and PTX against RCC cells, the phosphor-
ylation of PI3K/Akt was evaluated after stimulation by
DAC and/or PTX. In two RCC cell lines, although DAC
(2 μM) and/or PTX (2 nM) did not affect the total ex-
pression of PI3K or Akt, both DAC and PTX alone
decreased the phosphorylation of PI3K and Akt. More-
over, DAC significantly enhanced the suppression of
phospho-PI3K and phospho-Akt induced by PTX in two
RCC cell lines (Figure 3). These results suggest that
PI3K/Akt pathway may play a key role in the synergy of
DAC and PTX against RCC cells.
Discussion
A large number of basic experiments and clinical trials
of combination chemotherapy regimens have been per-
formed with the hope of removing the limitations of
current therapies for RCC. However, few of them have
attained a remarkable response and prognostic benefit to
patients [16]. Therefore, effective regimens of combin-
ation chemotherapy for RCC are highly sought.
Promising new antitumor agents usually appear as our
understanding of oncogenesis advances. Combination
chemotherapy of DAC and chemotherapeutic agents
have been investigated since 2004, the results suggesting
that DAC could increase the cytotoxicity of chemothera-
peutic agents against lung cancer cells and melanoma
cells in vitro [17,18]. In the previous study, we also
reported the synergistic growth suppression of DAC
with PTX in RCC [13]. DAC is a demethylation agent,
which was shown to suppress the proliferation of malig-
nant tumors by reactivating the expression of specific
methylated genes or causing genome-wide demethyla-
tion [19,20]. However, another study suggested that
DAC-induced antineoplastic activity was dependent on
DNA damage [21]. Whether DAC acts on tumors pri-
marily through its effect on DNA methylation or
through synergistic cytotoxicity with PTX remains
unknown.
In this study, we investigated the gene transcriptional
alteration by the cDNA microarray and revealed possible
molecular mechanism and pathways implicated in the
synergy of DAC and PTX against RCC cells. Several key
regulatory genes were identified and may play critical
roles in the synergy of these two agents. These include
lymphoid enhancer-binding factor 1 (LEF1), transform-
ing growth factor β-induced (TGFBI), C-X-C motif lig-
and 5 (CXCL5) and myelocytomatosis viral related
Figure 2 Confirmation of synergy-related genes of DAC and PTX by real-time PCR and primer sequences (A, B).
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B and T lymphoid-specific gene encoding a DNA-
binding protein of high mobility group proteins [22,23].
In addition, LEF1 is a member of the lymphoid-
enhancing factor/T-cell factor (LEF/TCF) family of tran-
scription factors, which acts through the Wnt/β-catenin
signaling pathway to regulate gene expression andFigure 3 DAC and PTX suppressed the activation of the PI3K/Akt path
blot.coordinate many cellular processes in normal develop-
ment and carcinogenesis [24-26]. A study showed that
the proliferation and invasion of the melanoma cell is
regulated by LEF1/TCF activity [27]. Upon Wnt stimula-
tion, LEF1 could combine with β-catenin and activate
Wnt-responsive target genes [28]. Our previous study
has confirmed that LEF1 can enhance the proliferationway significantly compared to DAC or PTX alone by Western
Han et al. World Journal of Surgical Oncology 2012, 10:183 Page 6 of 7
http://www.wjso.com/content/10/1/183of RCC cells and that suppressing the expression of
LEF1/β-catenin complex plays an important role in the
synergistic mechanism of DAC and PTX against RCC
cells [29]. TGFBI is a target of TGF-β and secreted into
the extracellular space, where it binds to fibronectin and
collagen as well as integrins to stimulate adhesion, mi-
gration, spreading, and proliferation in renal proximal
tubular epithelial cells [30,31]. Studies showed that
TGFBI was induced by TGF-β in the lung adenocarcin-
oma cell line and overexpression of TGFBI was asso-
ciated with some malignancies, such as RCC and
hemangioblastoma [32,33]. Our previous study has
demonstrated that TGFBI-promoted metastasis of RCC
cells depends on inactivation of the von Hippel-Lindau
(VHL) tumor suppressor and that TGFBI could be a
therapeutic target against RCC in the future [34].
CXCL5, a member of the CXC chemokine family, has
been shown to be involved in angiogenesis, tumor
growth, and metastasis. CXCL5 is upregulated signifi-
cantly in sporadic endometrioid endometrial adenocar-
cinomas compared to normal endometrium [35].
CXCL5 overexpression was also associated with late
stage gastric cancer and high N stage, suggesting CXCL5
is involved in the progression of gastric cancer, especially
in lymph node metastasis [36]. However, whether
CXCL5 could stimulate phenotypic responses in renal
epithelial cells with malignant progression remains un-
known. c-myc is a multifunctional, nuclear phosphopro-
tein that plays multiple roles in eukaryotic cells
including cell progression, differentiation, apoptosis and
neoplasia [37]. It interferes with the regulators of G1/S
transition, as well as other regulators of cell growth and
metabolism, inducing several translation factors and ad-
hesion molecules [38]. Alterations of the c-myc genomic
region are usually observed in prostate cancer [39-41]
and bladder cancer [42], however, genomic alterations of
c-myc are mostly subordinate for conventional RCC
with the exception of papillary renal cancer [43-45].
At present, the signaling pathways underlying the
synergy of DAC and PTX against RCC have not been
investigated. In this study, we found that some cell
cycle-related pathways were involved in the synergy of
both agents by IPA, such as cyclins, DNA replication
and cell cycle/mitotic regulation; these results are con-
sistent to our previous study. Moreover, we also
confirmed that the synergy of DAC and PTX may be
mediated by inhibiting the PI3K/Akt pathway. PI3K
could enhance production of PIP3 and trigger a signal-
ing cascade, which results in the activation of Akt
[46]. Because LEF1/β-catenin is a target of the PI3K/
Akt pathway, we speculated that synergistic suppres-
sion of LEF1/β-catenin expression by DAC and PTX is
dependent on the inactivation of the PI3K/Akt
pathway.Conclusion
In conclusion, we analyzed the overall gene expression
profiling by cDNA microarray and revealed the synergis-
tic mechanism of DAC and PTX against RCC. Our
results indicated that activation of the PI3K/Akt-LEF1/
β-catenin pathway could be suppressed synergistically by
these two agents and that the PI3K/Akt-LEF1/β-catenin
pathway participated in the synergy of the two agents.
More altered genes and pathways involved in the syn-
ergy should be investigated in the future.
Additional files
Additional file 1: DAC (A) and PTX (B, C) each caused dosage-
dependent cell growth suppression of RCC cells. DAC (0.5 and 1 μM)
increased the susceptibility of RCC cells to PTX (B for ACHN and C for NC 65
are shown). The combination of DAC and PTX caused synergistic growth
suppression in all two RCC cell lines by isobolographic analysis (D).
Additional file 2: Table S1 The top 10 up/down-regulated genes in
the three different conditions normalized by untreated control.
Additional file 3: Table S2 The top 10 up/down-regulated synergy-
related genes by DAC and PTX are shown in (A) and (B), and
synergy-related pathways by DAC and/or PTX are shown in (C).
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